KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$7.0 million.

  • Nektar Therapeutics' Change in Accured Expenses fell 20691.71% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.6 million, marking a year-over-year decrease of 22742.4%. This contributed to the annual value of $10.7 million for FY2024, which is 16216.98% up from last year.
  • Nektar Therapeutics' Change in Accured Expenses amounted to -$7.0 million in Q3 2025, which was down 20691.71% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Change in Accured Expenses registered a high of $14.2 million during Q1 2022, and its lowest value of -$41.3 million during Q4 2021.
  • For the 5-year period, Nektar Therapeutics' Change in Accured Expenses averaged around -$2.8 million, with its median value being $1.2 million (2025).
  • In the last 5 years, Nektar Therapeutics' Change in Accured Expenses crashed by 77070.06% in 2023 and then surged by 148956.31% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Change in Accured Expenses (Quarter) stood at -$41.3 million in 2021, then skyrocketed by 47.79% to -$21.5 million in 2022, then surged by 54.77% to -$9.7 million in 2023, then skyrocketed by 32.45% to -$6.6 million in 2024, then decreased by 6.35% to -$7.0 million in 2025.
  • Its last three reported values are -$7.0 million in Q3 2025, $2.7 million for Q2 2025, and $1.2 million during Q1 2025.